Stellar Biotechnologies' Partner Neovacs Reports Potent and Long-Lasting Biological Activity of IFN-Alpha-Kinoid Immunotherapy 4 Years After Patient Dosing in Lupus Phase I/IIa Trial

PORT HUENEME, CA--(Marketwired - Sep 17, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTD) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, today announced that its partner Neovacs (Alternext Paris: ALNEV) recently presented promising extended follow-up data from the Phase I/IIa clinical trial of IFNα-Kinoid, which is being evaluated for the treatment of Systemic Erythematosus Lupus ("SLE" or "lupus").

Stellar KLH™ is a primary component of Neovacs' proprietary immunotherapy Kinoid technology and is the carrier molecule in Neovacs' IFNα-Kinoid. Stellar and Neovacs recently entered into an expanded supply agreement to meet Neovacs' clinical and commercial requirements for KLH.

Neovacs presented the promising extended follow-up data during Lupus 2015, the 11^th International Congress on SLE, held September 2-6, 2015 in Vienna, Austria. The new data was collected as part of the Phase I/IIa extended follow-up study of six IFNα-Kinoid-treated patients. A link to the Neovac's Lupus 2015 Presentation Abstract can be found here http://bit.ly/1KdKC9X and to the related news release here http://bit.ly/1OcLcsl. These links are included for convenience only and are not incorporated into this press release.

Frank Oakes, President, Chief Executive Officer, and Chairman of Stellar Biotechnologies, Inc., said, "On behalf of our team at Stellar, I would like to extend our congratulations to Neovacs on this positive news and continuing advancement of their Kinoid technology. This is an important milestone for Neovacs which, we believe, reinforces the role of KLH as a key carrier molecule in immunotherapy treatments such as IFNα-Kinoid in lupus."

About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, please visit www.neovacs.fr.

About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (OTCQB: SBOTD) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the Stellar KLH knowledge base www.klhsite.org.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.